The European Forum on Antiphospholipid Antibodies was conceived as a multidisciplinary
network of different specialists working in the fields of internal medicine, haematology …

Atherosclerosis is a chronic inflammatory disease, resulting from hyperlipidemia and a
complex interplay of many environmental, metabolic, and genetic risk factors. The …

The presence of antiphospholipid antibodies (aPL) combined with venous or arterial
thrombosis, and/or obstetric complications defines the antiphospholipid syndrome (APS) …

The diagnosis of antiphospholipid syndrome (APS) relies on the detection of
antiphospholipid antibodies (aPL). Currently, lupus anticoagulant (LA), anticardiolipin (aCL) …

There is a growing body of literature suggesting that antiphospholipid antibodies develop for
a purpose, that they play several key roles in the innate immune response, and are only …

Atherosclerosis is characterized by infiltration in the lesions of cytokine-producing T cells
and macrophages, where oxidized LDL may play an important role. However, little is known …

Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by
recurrent thrombotic events and/or pregnancy morbidity in the presence of antiphospholipid …

Objective Immunoglobulin M (IgM) antibodies against phosphorylcholine (anti-PC) and
malondialdehyde (anti-MDA) are implicated in systemic lupus erythematosus (SLE) as …

Antiphospholipid antibodies (aPL) have been associated with different diseases. They are
defined as a large family of immunoglobulins (Ig) of either alloantibodies or autoantibodies …

The 10th International Congress on Antiphospholipid Antibodies (Sicily, Italy, September 29–
October 3, 2002)(Fig. 1) provided enlightening aspects on the recent developments in …